Affects : Actualité Affects en direct - P1 | Bourse Reflex
Accueil > Tags > Affects

  • Toutes les actualités en rapport avec « Affects »

02/05 07:30 Affects - ORAL PRESENTATION OF THERANEXUS AT THE 9TH EUROPEAN CONGRESS ON NARCOLEPSY 5 AND 6 MAY IN MONTPELLIER

23/04 07:30 Affects - THN102 OBTAINS INVESTIGATIONAL NEW DRUG STATUS FROM THE FOOD AND DRUG ADMINISTRATION (FDA)

19/04 18:00 Affects - THERANEXUS ANNOUNCES THE FIRST EUROPEAN APPROVAL FOR ITS PHASE 2 CLINICAL TRIAL WITH THN 102 IN PARKINSON'S DISEASE PATIENTS

19/04 17:45 Affects - Quantum Genomics enters a new phase of maturity with its BAPAIs Fast Growth strategic plan

15/11 07:30 Affects - Quantum Genomics announces recruitment of first patients in the NEW-HOPE arterial hypertension study in the United States

28/09 07:30 Affects - Theranexus files its registration document as part of its planned Initial Public Offering (IPO) on the Euronext Growth market in Paris

30/08 20:30 Affects - SES-imagotag: H1 2017 Strong sales performance Profitability temporarily affected

28/06 07:30 Affects - Quantum Genomics announces the design of its next Phase II trial in arterial hypertension, NEW-HOPE

31/05 08:30 Affects - Artprice fits perfectly into President Macron's Digital Europe Project

28/02 17:45 Affects - Genticel becomes Genkyotex: Genticel's General Meeting approves the strategic combination with GenKyoTex SA

30/01 18:00 Affects - BUSINESS UPDATE - FOURTH QUARTER 2016

22/12 13:00 Affects - Genticel and Genkyotex Announce Intention to Enter into Strategic Combination

09/09 07:00 Affects - Current operating income multiplied by 6; solid sales outlook for the second half-year

30/06 18:00 Affects - Quantum Genomics Initiates Phase IIa trial for Heart Failure, the second strategic initiative for its BAPAI therapeutic platform

26/04 18:00 Affects - Regulatory authorisations received in France to begin Phase IIa multicentric European trial for heart failure

21/04 19:45 Affects - PUBLICATION OF THE FIRST ISSUE OF GENTICEL'S SHAREHOLDER NEWSLETTER

02/07 08:00 Affects - Quantum Genomics speeds its development work in the field of heart failure

10/10 11:10 Affects - Second part of an exclusive interview with Thierry Ehrmann, CEO of Artprice.com (9 October 2011)

30/08 14:35 Affects - Take Aim: NASDAQ OMX and Prostate Cancer Foundation Team Up

28/05 12:29 Affects - GLOBAL REPORTING Les premiers résultats du « Readers' and Reporters' Survey 2010 » font l'objet de discussions à la Conférence de la GRI